Perfusion Imaging Evaluation for Ischemic Stroke on 6-24 Hours Undergoing Endovascular Thrombectomy (PESET)
Primary Purpose
Stroke, Acute Cerebral Infarction
Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Endovascular Thrombectomy
Endovascular Thrombectomy
Sponsored by
About this trial
This is an interventional prevention trial for Stroke, Acute Cerebral Infarction
Eligibility Criteria
Inclusion Criteria:
Clinical Inclusion Criteria:
- Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke
- Age ≥18 years
- NIHSS ≥ 6
- Endovascular thrombectomy can be initiated (femoral puncture) between 6 and 24 hours after time last know well
- No significant pre-stroke disability (pre-stroke mRS must be ≤ 3 )
- Patient/Legally Authorized Representative has signed the Informed Consent form
Imaging Inclusion Criteria:
- ICA or MCA-M1 or MCA-M2 or BA occlusion (carotid occlusions can be cervical or intracranial with or without tandem MCA lesions) as evidenced by MRA or 4D-CTA
- Target Mismatch Profile on CT perfusion or MR perfusion: ischemic core volume is ≤ 70 ml, mismatch ratio is >/= 1.2 )
Exclusion Criteria:
Clinical Exclusion Criteria:
- Other serious, advanced, or terminal illness (investigator judgment) or life expectancy is less than 90 days
- Subject with a co-morbid disease or condition that would confound the neurological and functional evaluations or compromise survival or ability to complete follow-up assessments
- Unable to undergo a contrast brain perfusion scan with either MRI or CT
- Pregnant
- Known serious sensitivity to radiographic contrast agents
- Treated with rtPA >6 hours after time last known well
- Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR > 3 (recent use of one of the new oral anticoagulants is not an exclusion if estimated GFR > 30 ml/min).
- Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS
- Current participation in another investigational drug or device treatment study
- Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency
- Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.
Neuroimaging Exclusion Criteria:
- ASPECTS score <6 on non-contrast CT (if patient is enrolled based on CT perfusion criteria)
- Evidence of intracranial tumor (except small meningioma), acute intracranial hemorrhage, neoplasm, subarachnoid hemorrhage, or arteriovenous malformation
- Significant mass effect with midline shift
- Evidence of internal carotid artery dissection
- Intracranial stent implanted in the same vascular territory, known history of arterial tortuosity, and/or other arterial disease that precludes the safe deployment/removal of the thrombectomy device
Sites / Locations
- Second Affiliated Hospital, School of Medicine, Zhejiang UniversityRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Endovascular Thrombectomy
Arm Description
Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
Outcomes
Primary Outcome Measures
Good Functional Independence
This outcome will look at the proportion of patients with mRS 0-2 at day 90.
Secondary Outcome Measures
Death
Death
Symptomatic Intracranial Hemorrhage
Defined as NIHSS worsening of 4 or more points associated with ICH within 24 hours of randomization
Full Information
NCT ID
NCT03502408
First Posted
March 29, 2018
Last Updated
November 21, 2022
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
1. Study Identification
Unique Protocol Identification Number
NCT03502408
Brief Title
Perfusion Imaging Evaluation for Ischemic Stroke on 6-24 Hours Undergoing Endovascular Thrombectomy
Acronym
PESET
Official Title
Perfusion Imaging Evaluation for Ischemic Stroke on 6-24 Hours Undergoing Endovascular Thrombectomy
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2018 (Actual)
Primary Completion Date
August 1, 2024 (Anticipated)
Study Completion Date
August 1, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study aims to evaluate the hypothesis that thrombectomy devices plus medical management leads to superior clinical outcomes in acute ischemic stroke patients at 90 days as compared to medical management alone in appropriately selected subjects with the Target Mismatch Profile and an MCA (M1 and M2 segment) or ICA occlusion or BA who have endovascular thrombectomy initiated between 6-24 hours after last seen well.
Detailed Description
Study design is a prospective, single-center study of acute ischemic stroke patients with large artery occlusion in 6-24 hours of stroke onset. According to patients or their family members' willing, patients who meet the inclusion criteria will be assigned to endovascular thrombectomy group with approved devices (only the devices listed in this protocol are approved for us) plus standard medical therapy or control group (standard medical therapy alone) after undergoing either CT Perfusion or MR Perfusion studies. Patients who have evidence of an ICA or MCA M1 or M2 or BA occlusion and a Target Mismatch Profile will be enrolled.
The intent of this study is to support thrombectomy beyond the currently labeled 8 hour indicated time limit in wake up, unclear onset, and late presenting ischemic stroke subjects, who currently have no other option besides medical management of their symptoms, with careful selection.
The study will enroll up to 55 patients. The primary endpoint, the modified Rankin Score, will be assessed at 3 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Acute Cerebral Infarction
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
55 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Endovascular Thrombectomy
Arm Type
Experimental
Arm Description
Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
Intervention Type
Procedure
Intervention Name(s)
Endovascular Thrombectomy
Intervention Description
Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
Intervention Type
Procedure
Intervention Name(s)
Endovascular Thrombectomy
Intervention Description
Procedure:Endovascular Thrombectomy Device: Solitaire™ FR Revascularization Device
Primary Outcome Measure Information:
Title
Good Functional Independence
Description
This outcome will look at the proportion of patients with mRS 0-2 at day 90.
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Death
Description
Death
Time Frame
90 days
Title
Symptomatic Intracranial Hemorrhage
Description
Defined as NIHSS worsening of 4 or more points associated with ICH within 24 hours of randomization
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical Inclusion Criteria:
Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke
Age ≥18 years
NIHSS ≥ 6
Endovascular thrombectomy can be initiated (femoral puncture) between 6 and 24 hours after time last know well
No significant pre-stroke disability (pre-stroke mRS must be ≤ 3 )
Patient/Legally Authorized Representative has signed the Informed Consent form
Imaging Inclusion Criteria:
ICA or MCA-M1 or MCA-M2 or BA occlusion (carotid occlusions can be cervical or intracranial with or without tandem MCA lesions) as evidenced by MRA or 4D-CTA
Target Mismatch Profile on CT perfusion or MR perfusion: ischemic core volume is ≤ 70 ml, mismatch ratio is >/= 1.2 )
Exclusion Criteria:
Clinical Exclusion Criteria:
Other serious, advanced, or terminal illness (investigator judgment) or life expectancy is less than 90 days
Subject with a co-morbid disease or condition that would confound the neurological and functional evaluations or compromise survival or ability to complete follow-up assessments
Unable to undergo a contrast brain perfusion scan with either MRI or CT
Pregnant
Known serious sensitivity to radiographic contrast agents
Treated with rtPA >6 hours after time last known well
Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR > 3 (recent use of one of the new oral anticoagulants is not an exclusion if estimated GFR > 30 ml/min).
Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS
Current participation in another investigational drug or device treatment study
Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency
Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.
Neuroimaging Exclusion Criteria:
ASPECTS score <6 on non-contrast CT (if patient is enrolled based on CT perfusion criteria)
Evidence of intracranial tumor (except small meningioma), acute intracranial hemorrhage, neoplasm, subarachnoid hemorrhage, or arteriovenous malformation
Significant mass effect with midline shift
Evidence of internal carotid artery dissection
Intracranial stent implanted in the same vascular territory, known history of arterial tortuosity, and/or other arterial disease that precludes the safe deployment/removal of the thrombectomy device
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
MIN LOU, Ph.D.
Phone
8657187784811
Email
loumingxc@vip.sina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
MIN LOU, Ph.D.
Organizational Affiliation
Second Affiliated Hospital, School of Medicine, Zhejiang University
Official's Role
Study Director
Facility Information:
Facility Name
Second Affiliated Hospital, School of Medicine, Zhejiang University
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310009
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
MIN LOU, Ph.D.
Phone
8657187784811
Email
loumingxc@vip.sina.com
First Name & Middle Initial & Last Name & Degree
MIN LOU, Ph.D.
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Perfusion Imaging Evaluation for Ischemic Stroke on 6-24 Hours Undergoing Endovascular Thrombectomy
We'll reach out to this number within 24 hrs